Schrödinger Posts Mixed Q4 Results Amid Strategic Business Model Shift
Computational drug discovery platform company Schrödinger Inc (NASDAQ:SDGR) reported financial results for the fourth quarter and full year 2025, delivering a bottom-line profit that handily beat analyst expectations while revenue came in slightly ahead of estimates. The company's shares were volatile in after-hours trading following the announcement, reflecting investor digestion of both the quarterly beat and a significant strategic shift in its software revenue model.
Earnings and Revenue Versus Estimates
For the critical fourth quarter, Schrödinger’s performance presented a clear split between earnings and sales growth.
- Earnings Per Share: The company reported net income of $32.5 million, or $0.44 per share on a non-GAAP basis. This result sharply contrasted with analyst expectations for a loss of $0.19 per share and reversed a net loss of $40.2 million in the same period last year.
- Revenue: Total revenue for Q4 2025 was $87.2 million, a modest 1.2% decrease year-over-year but slightly above the consensus estimate of approximately $85.1 million.
The substantial earnings beat was primarily driven by a significant $50.1 million in "Other Income," which includes gains from equity investments and changes in their fair value. This underscores the continued financial benefit Schrödinger derives from its stakes in various biotechnology startups it helped found.
Market Reaction and Strategic Pivot
The initial after-market stock reaction showed modest downward pressure. This movement appears less tied to the headline earnings beat and more to the company's detailed guidance and announcement of a fundamental change in its software business.
A key focus of the earnings release was Schrödinger's decision to accelerate its transition from traditional on-premise software licenses to a hosted, subscription-based model. While this shift is an industry standard that promises more predictable, ratable revenue and better aligns with customer infrastructure needs, it creates a near-term accounting headwind. Revenue that was previously recognized upfront for multi-year on-premise deals will now be recognized over the life of the contract.
Management explicitly warned that this transition "is expected to introduce short-to-medium term declines in software revenue," even though it does not impact cash flow or the underlying Annual Contract Value (ACV) of the business. This outlook likely tempered investor enthusiasm from the EPS beat.
Full-Year Highlights and Forward Guidance
For the full year 2025, Schrödinger demonstrated robust growth, though it remained unprofitable on a GAAP basis.
- Total revenue grew 23% to $255.9 million.
- Software revenue increased 11% to $199.5 million.
- Drug discovery revenue more than doubled to $56.4 million.
- Net loss improved significantly to $103.3 million, compared to a $187.1 million loss in 2024.
Looking ahead, the company's 2026 outlook centers on ACV growth rather than GAAP revenue, due to the software model transition. Software ACV is expected to grow 10-15% to a range of $218-$228 million. Drug discovery revenue is projected between $55-$65 million, and operating expenses are expected to be lower than 2025 levels.
Notably, Schrödinger introduced 2028 financial objectives, with a central goal of achieving positive adjusted EBITDA by the end of that year. This long-term framework emphasizes durable software growth, completion of the hosted transition, and disciplined cost management.
Platform and Pipeline Updates
The press release highlighted ongoing advancements in both its software platform and therapeutic pipeline:
- Platform: Recent introductions include RetroSynth, an AI-driven synthesis route planner, and strategic collaborations with Lilly TuneLab and Manas AI to integrate its physics-based models with external AI algorithms.
- Pipeline: The company is progressing its proprietary clinical programs, SGR-1505 (MALT1 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor), and noted positive developments from its equity stakes. This includes Structure Therapeutics' positive Phase 2b data for an oral obesity drug and Takeda's positive Phase 3 results for a psoriasis drug, for which Schrödinger is eligible for future milestones and royalties.
Conclusion
Schrödinger's fourth quarter showcased the dual nature of its business: solid core software growth supplemented by volatile but valuable returns from its equity investments. The market's muted reaction reflects the balancing act between a strong quarterly earnings beat and the communicated near-term pressure on revenue growth as the company pivots its sales model. The success of this transition to a hosted platform, alongside the continued maturation of its drug discovery portfolio, will be critical to achieving its 2028 profitability goal.
For a detailed look at Schrödinger's upcoming earnings estimates and historical performance, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
